T1	p 137 170	after major gynecologic surgery .
T2	p 349 446	360 ASA physical status I-III patients undergoing total abdominal hysterectomy ( TAH ) . Subjects
T3	p 713 726	four patients
T4	p 764 784	systolic hypotension
T5	p 801 813	anesthesia .
T6	p 836 898	patients receiving droperidol became sedated . Postoperatively
T7	p 901 920	patients developing
T8	i 22 95	prophylactic ondansetron , droperidol , perphenazine , and metoclopramide
T9	i 233 293	ondansetron , droperidol , perphenazine , and metoclopramide
T10	i 353 356	ASA
T11	i 399 435	total abdominal hysterectomy ( TAH )
T12	i 474 581	i.v. , one of ondansetron 4 mg , droperidol 1.25 mg , perphenazine 5 mg , metoclopramide 10 mg , or placebo
T13	i 665 679	metoclopramide
T14	i 733 744	ondansetron
T15	i 855 865	droperidol
T16	i 1069 1088	antiemetic rescue .
T17	i 1148 1161	. ondansetron
T18	i 1173 1183	droperidol
T19	i 1199 1213	perphenazine (
T20	i 1234 1237	SES
T21	i 1255 1262	placebo
T22	i 1285 1299	Metoclopramide
T23	i 1327 1338	ondansetron
T24	i 1341 1351	droperidol
T25	i 1358 1370	perphenazine
T26	i 1435 1447	perphenazine
T27	i 1500 1512	perphenazine
T28	i 1565 1568	TAH
T29	o 117 136	nausea and vomiting
T30	o 199 207	efficacy
T31	o 617 628	Hypotension
T32	o 764 784	systolic hypotension
T33	o 910 969	developing severe nausea , retching , or vomiting , defined
T34	o 973 995	severe emetic sequelae
T35	o 1069 1088	antiemetic rescue .
T36	o 1460 1472	side effects